| Name | Title | Contact Details |
|---|
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Complete Testing Solutions is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.
Eos Biotechnology , Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.